10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors
Abstract
4019
Background:
Inhibitors of Programmed Cell Death Protein-1 (PD-1) have demonstrated remarkable activity in dMMR/MSI-H cancers, leading to the first tissue agnostic FDA approval for an oncologic indication. We report herein results of long-term follow up of KEYNOTE-016, the first study to demonstrate pan-tumor activity of the PD-1 inhibitor pembro in dMMR/MSI-H solid tumors.
Methods:
KEYNOTE-016 was a multi-center open-label phase 2 study evaluating pembro in patients with advanced colorectal cancer (CRC) (Cohort A) or non-CRC solid tumors (Cohort C) that were dMMR and had progressed after ≥1 prior line of therapy (or ≥2 prior lines for CRC). Eligible patients were age ≥ 18, and had measurable disease per RECIST 1.1. Patients with active CNS metastases, who were on immunosuppressive therapy, had autoimmune disease, or were previously treated with immune checkpoint inhibitors were excluded. Patients received pembro IV every 2 weeks until progression, intolerance, withdrawal of consent or up to a maximum of 2 years.
Results:
Between 9/2013 - 9/2017, 88 patients (Cohort A: 41; Cohort C: 47) enrolled at 7 sites and received ≥1 dose of pembro. Tumor types enrolled on Cohort C included endometrial (N = 15), pancreatic (N = 9), small intestinal (N = 5), gastroesophageal (N = 5), biliary (N = 4), ampullary (N = 4), and other (N = 5). Median follow up time was 49.7 mos for all patients and 99.8 mos for alive patients. Objective response rate (ORR) was 58% with 23 partial (PR) and…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 47 participants or records.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.